RE:RE:RE:RE:RE:RE:Antibody-drug conjugates (ADCs) company CCO departsOctober 31, 2022 - Daiichi Sankyo sets new highs for AstraZeneca-partnered ADC cancer drug Enhertu
The Japanese pharma on Monday upped its forecast for Enhertu this year by more than $400 million, projecting it could haul in about $1.3 billion in sales this year.
Daiichi recently noted that Enhertu hit on a primary endpoint for a Phase III postmarket commitment trial after winning approval as a third-line treatment for HER2-positive breast cancer.
https://endpts.com/daiichi-sankyo-sets-new-highs-for-astrazeneca-partnered-cancer-drug-enhertu/